A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (greater than or equal to 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy.

Trial Profile

A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (greater than or equal to 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Planned end date changed from 1 Feb 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 20 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top